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Abstract 
Purpose: Acute respiratory distress syndrome is a life-threatening form of respiratory failure without an established 
pharmacological treatment. Recently, macrolides have been found to be beneficial in cases of acute lung injury, but 
evidence is limited.
Materials and methods: This single-centre retrospective cohort evaluation of hospitalized patients with sepsis-asso-
ciated acute respiratory distress syndrome aimed to assess the impact of azithromycin on clinical outcomes by using 
a propensity score analysis. All data were collected prospectively as part of ongoing research on high-resolution com-
puted tomography of acute respiratory distress syndrome. The primary outcome was 60-day mortality; the secondary 
outcome was the number of ventilator-free days.
Results: Twenty-nine of 125 patients with sepsis-associated acute respiratory distress syndrome (23.2 %) received 
azithromycin within 24 h after acute respiratory distress syndrome diagnosis. After adjusting for potentially confound-
ing covariates, azithromycin use was associated with lower 60-day mortality (hazard ratio, 0.31; 95 % confidence 
interval, 0.11–082; P = 0.02) and a shorter time to successful discontinuation of mechanical ventilation.
Conclusions: Azithromycin use was associated with decreased mortality and ventilator dependency in patients with 
sepsis-associated acute respiratory distress syndrome. Further well-designed prospective studies are needed.
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Background
Acute respiratory distress syndrome (ARDS) is a life-
threatening form of respiratory failure that affects a het-
erogeneous population of critically ill patients. Although 
overall mortality appears to be decreasing in recent years 
because of improvements in supportive care, the mor-
tality rate from ARDS is approximately 30–40  %, and 
therefore is still high (Rubenfeld et al. 2005; Zambon and 
Vincent 2008; Force et  al. 2012). At present, there is no 
proven effective pharmacological therapy for ARDS.
Macrolides have immunomodulatory effects in addi-
tion to antimicrobial effects. Macrolides have been 
shown to reduce mortality in many acute lung injury ani-
mal models (Tamaoki 2004; Sato et al. 1998; Amado-Rod-
riguez et al. 2013). In humans, Walkey and Wiener (2012) 
recently proposed that macrolides may benefit patients 
with acute lung injury. Walkey reported that the most 
commonly administered macrolide was erythromycin, 
followed by azithromycin (40 %) in their registry.
Until 2011, erythromycin was the only macrolide 
that could be used by intravenous injection in Japan, 
but erythromycin has many side effects and drug 
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interactions, so we did not routinely use intravenous 
erythromycin in daily clinical practice. In cases of severe 
pneumonia, we have used quinolone with beta-lactam 
antibiotics. Intravenous azithromycin has been approved 
for clinical use since September 2011 in Japan. Azithro-
mycin is safer and easier to use than erythromycin, and 
since the publication of Walkey’s report, we routinely use 
azithromycin for patient with acute respiratory failure 
from July 2012.
Until now, to our best knowledge, there is no evi-
dence except for Walkey’s report regarding the impact of 
azithromycin on clinical outcomes in patients with sep-
sis-associated ARDS.
Therefore, we conducted this retrospective observa-
tional study to assess the impact of intravenous azithro-
mycin administration on clinical outcomes in patients 




We performed a retrospective cohort study of patients 
with ARDS who underwent intensive care during the 
period from October 2004 to April 2015 at a tertiary aca-
demic teaching hospital in Kumamoto, Japan.
This protocol (IRB no. 289) was approved by the Insti-
tutional Review Board at Saiseikai Kumamoto Hospital. 
Written informed consent was obtained from all sub-
jects or surrogates in accordance with the Declaration 
of Helsinki. If patients were minors, we obtained written 
informed consent from legal guardians on behalf of the 
minors.
The primary outcome was 60-day mortality. Addition-
ally, the duration of mechanical ventilation and predic-
tors of 60-day mortality were evaluated.
All data were collected prospectively as a part of ongo-
ing research on high-resolution computed tomogra-
phy (HRCT) scores of ARDS patients [portions of these 
results were previously published (Ichikado et al. 2012)]. 
All patients were directly admitted to the intensive care 
unit from the emergency department.
The following patients were excluded: those under 
15 years of age, those being treated with anticancer drugs 
or radiation, unsuitable cases such as those involving 
hematologic disease, and those in the terminal stage of 
advanced cancer.
Demographics, clinical features, clinical data on admis-
sion, and HRCT data were obtained for all patients 
within 24 h of admission.
ARDS was defined on the basis of the Berlin definition 
(Force et al. 2012) of ARDS (between 2013 and 2015) and 
the American–European consensus conference on ARDS 
(Bernard et al. 1994) (between 2004 and 2012). Patients 
diagnosed based on the American–European consensus 
conference definition were re-evaluated to determine 
whether they met the Berlin definition. All patients were 
treated using a lung-protective strategy designed by the 
ARDS Network and according to clinical practical guide-
lines for acute lung injury and ARDS published by the 
Japanese Respiratory Society (2010). Sepsis was defined 
on the basis of the American College of Chest Physicians/
Society of Critical Care Medicine criteria (Bone et  al. 
1992). We divided sepsis into two categories: pulmonary 
and non-pulmonary.
Interventions
Before June 2012, there was no patient with sepsis asso-
ciated ARDS who treated with macrolide. Since July 
2012, we use intravenous azithromycin for patients with 
sepsis associated ARDS within 24 h of ARDS diagnosis. 
Azithromycin therapy was continued for 5  days if there 
was no reason to cease administration, such as side 
effects and arrhythmia, but discontinuation of azithromy-
cin was at the discretion of the attending physician. We 
did not have specific information about whether patients 
were treated with oral or intravenous macrolides before 
admission. No patient was treated with extracorporeal 
membrane oxygenation therapy in this study cohort.
Statistical analysis
We summarized baseline characteristics by using per-
centages for categorical variables and medians and 
interquartile ranges (IQRs) for continuous variables; 
comparisons between groups were performed using the 
Mann–Whitney rank-sum test and Fisher’s exact test, 
respectively. Survival time in days is reported as the 
median (95  % confidence interval [CI]), and was cal-
culated from admission until mortality from any cause 
within the study period. Patients were censored if they 
were alive at 60 days. Patients who were discharged home 
before day 60 were considered to be alive at day 60.
Survival curves were plotted using Kaplan–Meier 
methods. Log-rank tests were used to compare differ-
ences in survival. Time to successful discontinuation of 
mechanical ventilation was evaluated as described previ-
ously (Walkey and Wiener 2012).
Adjusted Cox regression modelling was performed 
using a stepwise selection of variables based on the 
Akaike information criterion. Variables that may have 
influenced clinical outcome included age, sex, serum 
albumin level, serum lactate dehydrogenase level, serum 
C-reactive protein level, McCabe and Jackson classifica-
tion, Acute Physiology and Chronic Health Evaluation 
II (APACHE II) score, PaO2/FiO2 ratio, white blood cell 
count, serum antithrombin III level, presence of cirrhosis, 
presence of pulmonary sepsis, Sequential Organ Failure 
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Assessment (SOFA) score, severity of ARDS based on the 
Berlin definition, disseminated intravascular coagulation 
(DIC) score, HRCT score of the lungs at admission, and 
azithromycin use. The DIC score was based on the DIC 
scoring system proposed by the Japanese Association for 
Acute Medicine (Gando et al. 2013). The HRCT score of 
the lungs was calculated as previously described (Ichi-
kado et al. 2002).
We also estimated adjusted relationships between 
treatment and outcome using the Cox proportional haz-
ards regression model via inverse probability of treatment 
weighting (IPTW) using a propensity score. The weights 
were based on the probability of receiving azithromycin. 
We used logistic regression models to estimate the pro-
pensity to receive azithromycin versus no azithromycin. 
The model included all variables mentioned above. All 
tests were two-sided and performed at a significance level 
of 0.05. We used the R statistical package (version 3.0.1; 
The R Foundation for Statistical Computing, Vienna, 
Austria) for all analyses.
Results
Initially, 185 patients with ARDS were identified, of 
whom 125 met the criteria for sepsis-associated ARDS. 
Baseline characteristics are shown in Table 1. Fifty-eight 
of 125 (46.4 %) patients died within 60 days.
Twenty-nine of 125 (23.2 %) patients with sepsis-asso-
ciated ARDS were administered intravenous azithro-
mycin within 24  h of an ARDS diagnosis. The median 
duration of azithromycin use after ARDS diagno-
sis was 5  days (IQR, 4–5  days); the mean duration was 
4.4 ±  1.0  days. Table  2 shows a comparison of baseline 
characteristics between patients treated with azithro-
mycin versus those who were not. There were 10 deaths 
(34.5 %) in the azithromycin group and 48 deaths (50 %) 
in the control group; the difference in survival was not 
significant (log-rank test; P = 0.167) (Fig. 1). There were 
significant differences between the two groups in the 
cause of ARDS (P = 0.048), PaO2/FiO2 ratio (P = 0.045), 
serum albumin level (P = 0.002), DIC score (P = 0.028), 
and platelet count (P = 0.003).
After adjustment for confounding covariates, azithro-
mycin use was associated with lower mortality (adjusted 
hazard ratio [HR] 0.38; 95  % CI 0.18–0.79; P  =  0.009) 
(Fig. 2).
In the adjusted analysis, APACHE II score (adjusted HR 
1.09; 95 % CI 1.03–1.15; P = 0.004), CT score (adjusted 
HR 1.22; 95 % CI 1.10–1.35; P < 0.001; HR expressed as 
mortality change per 10 % increase in area of attenuation 
with traction bronchiectasis on HRCT), and DIC score 
(adjusted HR: 1.36; 95  % CI 1.17–1.59; P  <  0.001) were 
also independently associated with a poor prognosis in 
the regression model (Table 3).
IPTW estimators with propensity score adjustment 
also showed that azithromycin use was associated with 
lower mortality (HR, 0.31; 95 % CI, 0.11–0.82; P = 0.02).
 Time to successful discontinuation of mechanical ven-
tilation was shorter in patients treated with azithromy-
cin than in patients who were not (Fig. 3) (adjusted HR 
for successful ventilation discontinuation: 2.22; 95  % CI 
1.24–3.99; P = 0.007).
Discussion
In this study, we observed lower mortality and a shorter 
duration of mechanical ventilation use in patients with 
sepsis-associated ARDS who received intravenous 
azithromycin within 24 h of sepsis-related ARDS diagno-
sis. We also identified associations between 60-day mor-
tality, DIC score, and CT score in this cohort.
Azithromycin use within 24  h of diagnosis was asso-
ciated with improved outcomes in patients with sepsis-
associated ARDS. Our result is consistent with Walkey’s 
Table 1 Baseline characteristics of study
n (%), median [IQR]
APACHE acute physiology and chronic health evaluation, ARDS acute respiratory 
distress syndrome, AZM azithromycin, DIC disseminated intravascular 
coagulation, FDP fibrin/fibrinogen degradation products, SOFA Sequential Organ 
Failure Assessment score, WBC white blood cell count
Factor Group Overall
N = 125
Age,y 75 [66, 82]
Sex M/F 85(68.0)/40 (32.0)
Cirrhosis No/Yes 112 (89.6)/13(10.4)
Sepsis Pulmonary 78 (62.4)
Nonpulmonary 47 (37.6)
APACHE.II 23 [18, 27]
McCabe 1/2/3 114 (91.2)/5(4.0)/6(4.8)
ARDS severity Mild 10 (8.0)
Moderate 58 (46.4)
Severe 57 (45.6)
SOFA 7 [5, 11]
PaO2/FiO2, mmHg 106.80 [75.1, 139.7]
CT.score 213.3 [184.8, 268.5]
Albumin, g/dL 2.8 [2.40, 3.20]
WBC 9600 [4200, 14,400]
C-reactive protein, mg/dL 15.94 [9.01, 25.70]
Lactate dehydrogenase, IU/L 308 [246, 434]
DIC score 3 [2, 4]
FDP, mg/L 11.10 [1.50, 170.70]
Antithrombin III  % 66.00 [52.00, 80.00]
Platelet, X104 17.90 [10.10, 26.40]
D.dimer.μg/ml. 5.60 [2.70, 11.00]
AZM use (%) 29(23.2)
Death (%) 58 (46.4)
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report showing that macrolide use was associated with 
lower 180-day mortality (HR 0.46; 95  % CI 0.23–0.92) 
(Walkey and Wiener 2012).
There are several reports of macrolide use leading to 
clinical benefits in patients with infection, especially 
in severe cases of pneumonia and sepsis (Restrepo 
et  al. 2009; Kumar et  al. 2010; Martin-Loeches et  al. 
2010; Sligl et  al. 2014; Garin et  al. 2014). Because sep-
sis is the most common cause of ARDS, macrolide use 
may lead to improved outcomes in sepsis-associated 
ARDS, but until now, there has been no evidence to 
support Walkey’s report. To our knowledge, this is the 
first report regarding the impact of a macrolide on mor-
tality in patients with ARDS diagnosed by the Berlin 
definition.
We suggest that the survival benefit of azithromycin 
in sepsis-associated ARDS is due to anti-inflammatory 
and immunomodulating effects rather than antimicro-
bial activity. Walkey and Wiener also proposed that the 
anti-inflammatory and immunomodulatory effects of 
macrolides may benefit patients with acute lung injury 
(Walkey and Wiener 2012). Macrolides have been shown 
to prevent the production of pro-inflammatory media-
tors, cytokines, and reactive oxygen species (Kanoh and 
Rubin 2010), which is potentially the basis for their ben-
eficial effects.
Pneumonia is the most common cause of ARDS. In 
our cohort, 62.4 % of patients presented pneumonia. The 
current Infectious Diseases Society of America/Ameri-
can Thoracic Society guidelines for community-acquired 
pneumonia (CAP) (Mandell et  al. 2007) recommend 
azithromycin use in patients with severe CAP requiring 
hospitalization on an intensive care unit. Our study sup-
ports the current recommendation. Early intervention 
with azithromycin may suppress excess inflammation 
that could lead to ARDS and multiple organ failure from 
severe pneumonia.
There are studies that found that macrolide use did not 
improve mortality from pneumonia (Asadi et  al. 2012; 
Postma et al. 2015), but these studies included mild and 
Table 2 Baseline Characteristics of cohort stratified by azithromycin use
n (%), median [IQR]
APACHE acute physiology and chronic health evaluation, ARDS acute respiratory distress syndrome, AZM azithromycin, DIC disseminated intravascular coagulation, 
FDP fibrin/fibrinogen degradation products, SOFA Sequential Organ Failure Assessment score
Factor Group Treatment P value
No-AZM AZM
N 96 29
Age (years) 76.5 [67, 82.25] 70 [65, 81] 0.35
Sex M/F 66 (68.8)/30 (31.2) 19 (65.5)/10 (34.5) 0.821
Cirrhosis Yes 10 (10.4) 3 (10.3) 1
Sepsis pulmonary 55 (57.3) 23 (79.3) 0.048
Nonpulmonary 41 (42.7) 6 (20.7)
APACHE.II 23 [18, 26] 24 [21, 27] 0.462
McCabe 1/2/3 88 (91.7)/3 (3.1)/5 (5.2) 26 (89.7)/2 (6.9)/1 (3.4) 0.63
ARDS severity Mild 5 (5.2) 5 (17.2) 0.113
Moderate 45 (46.9) 13 (44.8)
Severe 46 (47.9) 11 (37.9)
SOFA 7 [5, 11] 9 [7, 12] 0.143
PaO2/FiO2 100.45 [70.97, 132.70] 114.20 [84.50, 180.00] 0.045
CT.score 214.05 [184.80, 265.60] 211.70 [188.10, 268.50] 0.667
Alb, g/dL 2.90 [2.58, 3.30] 2.50 [2.20, 3.00] 0.002
WBC 10,450 [5250, 14,400] 7300 [2300, 12,200] 0.055
C-reactive protein, mg/dL 15.33 [8.68, 25.07] 19.69 [10.22, 30.10] 0.239
Lactate dehydrogenase, IU/L 312 [248.25, 436.50] 301 [233.00, 434.00] 0.621
DIC score 2 [2, 4] 4 [2, 5] 0.028
FDP, mg/L 11.00 [6.72, 18.10] 11.90 [9.30, 20.00] 0.382
AntithrombinIII,  % 66.50 [52.75, 81.25] 65.00 [51.00, 79.00] 0.527
PLT,X104 18.35 [11.93, 28.30] 12.40 [7.70, 18.40] 0.003
D.dimer.μg/ml 5.95 [2.48, 11.00] 4.60 [3.10, 9.30] 0.398
Death (%) 48 (50.0) 10 (34.5) 0.202
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moderate CAP that has low mortality, so a beneficial 
effect on mortality may not be detected easily. Another 
study found that macrolide use did not improve mor-
tality in severe infection (Giamarellos-Bourboulis et  al. 
2014). A recent prospective randomized study assessing 
the efficacy of clarithromycin in patients with systemic 
inflammatory response syndrome due to acute pyelo-
nephritis, acute intra-abdominal infection, or primary 
Gram-negative bacteraemia did not show an advantage 
in overall mortality (Giamarellos-Bourboulis et al. 2014). 
However, researchers reported that clarithromycin use 
shortened the time to resolution of infection, especially 
in severe sepsis/shock patients, and decreased hospi-
talization cost. Further, a survival benefit was observed 
among patients with septic shock and multiple organ 
dysfunction syndrome in subgroup analyses (Giamarel-
los-Bourboulis et al. 2014).
Walkey reported that among patients with acute lung 
injury who were administered a macrolide, erythromycin 
Fig. 1 Unadjusted Kaplan–Meier survival curves for patients with 
acute respiratory distress syndrome treated with and without azithro-
mycin
Fig. 2 Survival curves for the association between azithromycin 
use and 60-day mortality from the Cox proportional hazards model, 
adjusted for age, Acute Physiology and Chronic Health Evaluation II 
(APACHE II), computed tomography scores, and disseminated intra-
vascular coagulation scores
Table 3 Cox proportional hazards model results for 60-day 
mortality
APACHE acute physiology and chronic health evaluation, AZM azithromycin, CI 
confidence interval, DIC disseminated intravascular coagulation
a Expressed as mortality change per 10 % increase in area of attenuation with 
traction bronchiectasis on high-resolution CT
Factor Hazard.ratio (95 % CI) P value
APACHE.II 1.09 (1.03–1.15) 0.004
CT.score 1.22a (1.10–1.35) <0.001
DICscore 1.36 (1.17–1.59) <0.001
AZM use 0.38 (0.18–0.79) 0.009
Age 1.02 (1.00–1.05) 0.08
Fig. 3 Survival curves for the association between azithromycin use 
and successful discontinuation of mechanical ventilation at 28 days 
from the Cox proportional hazards model, adjusted for adjusted for 
age, Acute Physiology and Chronic Health Evaluation II (APACHE 
II), computed tomography scores, and disseminated intravascular 
coagulation scores
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was the most common (57  %), followed by azithromy-
cin (40  %) (Walkey and Wiener 2012). Azithromycin is 
the only macrolide that was used in our study popula-
tion, because azithromycin has fewer drug interactions 
and fewer side effects than erythromycin, and intrave-
nous clarithromycin is not presently available in Japan. 
We selected an azithromycin course of 5 days based on 
a previously reported median duration of macrolide use 
of 4 days in acute lung injury (Walkey and Wiener 2012). 
We do not know if a 4–5 day course of a macrolide is long 
enough to develop favourable effects in patients with 
ARDS, or if there is a difference in optimal therapy dura-
tion between erythromycin and azithromycin, because 
they have quite different intracellular half-lives; azithro-
mycin has a much longer half-life (40–68 h) than eryth-
romycin. We also do not know whether an oral macrolide 
improves clinical outcomes in patients with sepsis-asso-
ciated ARDS because of differing bioavailability.
In this study, we observed that the CT score and DIC 
score (meaning the presence of DIC) were useful inde-
pendent prognostic factors for sepsis-associated ARDS. 
We had reported the utility of a CT score as a prognos-
tic factor in ARDS (Ichikado et al. 2006, 2012), and that 
result has been reproduced in this study.
The DIC scoring system was proposed by the Japanese 
Association for Acute Medicine, and it has been reported 
that it exhibits good prognostic value in predicting mul-
tiple organ dysfunction syndrome and a poor prognosis 
in patients with severe sepsis (Gando et al. 2013). In this 
study, the DIC score was useful to assess prognosis in 
patients with sepsis-associated ARDS. Progression from 
ARDS to multiple organ failure was once thought to be 
caused by severe ARDS-induced hypoxemia. However, 
despite advances in respiratory care, many cases pro-
gress to multiple organ failure, the onset mechanisms of 
which are still unknown. Several investigators have pre-
viously reported patients with ARDS as having coagu-
lopathy, both systemic and in the alveolar compartment 
(Bajaj and Tricomi 1999; Ware et al. 2003). Some studies 
have implicated activation of the coagulation cascade and 
impaired fibrinolytic activity as pathogeneses of pneumo-
nia and acute lung injury (Gunther et al. 2000) (Schultz 
et al. 2006). Recently, several investigators have reported 
on the relationship between coagulopathy and proin-
flammatory events causing organ injury (Abraham 2000) 
(Coughlin 2000). Azithromycin has been reported to 
have immunomodulatory and anti-inflammatory activi-
ties, as well as anti-coagulant effects via platelet-activat-
ing factor mediated platelet aggregation (Tsoupras et al. 
2011). From the viewpoint of coagulopathy in the patho-
genesis of ARDS, azithromycin might have contributed 
to an improvement in survival in sepsis-associated DIC. 
Further study is needed to clarify the interaction between 
azithromycin and coagulopathy in ARDS.
Our study has several limitations. First, this study is 
from a single centre and is retrospective and observa-
tional in design. Patients with ARDS who were treated 
with azithromycin were included in this cohort recently, 
and there might have been improvements in supportive 
care over the 10  years that caused differences in out-
comes between patients treated with a macrolide and 
those who were not (Additional file 1). Second, the sam-
ple size was small, especially in the azithromycin group, 
which greatly increases the risk of random error. We 
adjusted for overt biases by applying IPTW using pro-
pensity scores to resolve problems created by unequal 
chances of receiving treatment. However, we cannot rule 
out the possibility that unmeasured confounding factors 
might have affected our results. Because of these poten-
tial limitations, the data should be interpreted with cau-
tion. Third, the study only involved sepsis-associated 
ARDS, and therefore this result cannot be applied to 
ARDS caused by trauma, aspiration, or other factors. 
Fourth, we do not know valuable information about oral 
macrolide use before presentation. Fifth, this study did 
not contain a valuable microbial analysis.
Conclusions
In conclusion, we observed lower mortality and a shorter 
duration of mechanical ventilation in patients with sep-
sis-associated ARDS who received intravenous azithro-
mycin within 24  h of ARDS diagnosis according to the 
Berlin definition. We also identified associations with 
60-day mortality, DIC score, and CT score in this cohort. 
A further well-designed study is needed to determine 
whether azithromycin improves morality in sepsis-asso-
ciated ARDS.
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